JAMA Oncology

04/01/2026

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. https://ja.ma/4tkLDr8

04/01/2026

In the BRIGHT-2 phase 3 randomized clinical trial, bireociclib plus fulvestrant significantly prolonged median progression-free survival for patients with hormone receptor–positive, ERBB2-negative advanced after prior endocrine therapy progression, compared to placebo plus fulvestrant. Improvements in objective response rate and disease control rate were observed for bireociclib-treated patients.

Safety outcomes were consistent with other cyclin-dependent kinase 4/6 inhibitors, including manageable rates of diarrhea and neutropenia. These findings support bireociclib plus fulvestrant as a treatment option for advanced breast cancer after endocrine progression.

https://ja.ma/4rKeVhJ

03/31/2026

Incidentally detected spleen length ≥140 mm or volume ≥500 mL was associated with markedly elevated 5-year risk for hematologic cancer, liver cancer, and cirrhosis in adults from Denmark and the UK.

This cohort study evaluates relative and absolute risks of hematologic cancers, cirrhosis, and liver cancer according to spleen length and volume in individuals with incidentally detected splenomegaly.

03/30/2026

The 2025 federal restrictions are projected to cause over 1 million missed exams and over 150 excess deaths within 2 years, with substantial impact on younger and vulnerable adults. https://ja.ma/4ca3YkS

03/29/2026

💬 Editorial by Asona Lui, MD, PhD, and Charles R. Thomas Jr, MD:

Stereotactic radiation offered modest symptom relief and better long-term neurocognitive outcomes than hippocampal-avoidance whole brain radiation, but was associated with higher rates of new brain metastases and salvage whole brain radiotherapy.

https://ja.ma/4ccsm5l

03/29/2026

From JAMA: The Medicare Care Model (OCM) was associated with modest reductions in Medicare payments for beneficiaries receiving for cancer; however, overall program costs exceeded these spending reductions.

https://ja.ma/41ynC3X

03/29/2026

Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern , but not for those with lepidic pattern alone. https://ja.ma/4lV2vSZ

03/28/2026

When lung cancer has spread beyond the lungs, this is known as stage IV (4), or metastatic, lung cancer.

Treatment at this stage usually focuses on systemic therapy, medications prescribed by a medical oncologist, such as targeted therapy, immunotherapy, antibody-drug conjugates, or chemotherapy, that travel through the bloodstream to treat cancer cells throughout the body.

📄 This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic and which patients might be considered for this treatment.

https://ja.ma/4uU13UK

03/28/2026

Ocular toxic effects including keratopathy, blurred vision, cataract progression, and uveitis were common but generally reversible during mirvetuximab soravtansine therapy for FRα-positive gynecologic cancers. https://ja.ma/4m4mpuQ

03/27/2026

In a cohort study including more than 11 million adults across 54 US health systems and the UK Biobank, a transparent pancreatic ductal adenocarcinoma (PDAC) Risk Model for Earlier Detection (PRIME) was developed and externally validated for predicting incident pancreatic ductal adenocarcinoma ( ).

PRIME uses 19 routinely available demographic, clinical, and laboratory predictors to identify individuals at elevated risk, achieving strong discrimination and calibration both in US and international populations.

Patients in the top 1% of predicted risk were more than seven times more likely to develop than average-risk individuals. This model enables population-level stratification and provides a foundation for targeted biomarker testing and multistage early detection strategies in routine care.

https://ja.ma/4byTLOO

03/27/2026

A 52-year-old woman had presented with persistent inflammatory edema of the lower limb and a history of squamous cell carcinoma.

What is your diagnosis?

https://ja.ma/41hlaPr

03/27/2026

Among men with undergoing hormone therapy, inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. https://ja.ma/4v1QbED